Medicines Australia and AusBiotech say COVID-19 vaccine patent waiver will not speed up global vaccination

15 September 2021 - Medicines Australia and AusBiotech, the peak bodies representing the Australian innovative pharmaceutical and biotechnology sectors, urge ...

Read more →

A court decision on “skinny labeling” another challenge for less expensive drugs

13 September 2021 - Brand name drugs, such as apixaban (Eliquis) and lenalidomide (Revlimid), account for approximately 80% of US drug ...

Read more →

Reimagining pharmaceutical market exclusivities: should the duration of guaranteed monopoly periods be value based?

13 September 2021 - The amount of time in which brand pharmaceutical markets are protected does not correspond with the products’ ...

Read more →

Joint statement of support for an Australian Patent Box

13 September 2021 - Australia’s health innovators support the introduction of a Patent Box, and we welcome this initiative by the ...

Read more →

FDA orphan drug approval: Octapharma’s Octagam 10% receives 7 years of market exclusivity for adult dermatomyositis

30 August 2021 - Octagam 10% expected to become the first treatment option for adults with rare immune-mediated inflammatory disease. ...

Read more →

J&J and Pfizer quietly resolve Remicade biosimilar lawsuit

27 July 2021 - In 2017, Pfizer filed a lawsuit against J&J alleging that the company undertook anticompetitive practices in a ...

Read more →

After repeated losses in the U.S., Catalyst wins a victory in Canada over a rare disease drug

3 June 2021 - In an unexpected move, Canada’s Federal Court quashed the approval of a rare disease drug after ...

Read more →

Suspend intellectual property rights for COVID-19 vaccines

28 May 2021 - Waivers are essential for global vaccine equity ...

Read more →

Vaccine patent waivers deserve a warning label

13 May 2021 - The move to suspend patents on COVID-19 vaccines opens up a major risk to the way the ...

Read more →

International IP protection at risk for COVID-19 vaccines

11 May 2021 - The global biotech industry is united in its drive for equitable access to COVID-19 vaccines, but ...

Read more →

America wants to waive patent protection for vaccines

8 May 2021 - But it will not have an immediate effect on supplies. ...

Read more →

US wary of boosting China biotech with COVID vaccine patent waiver

9 May 2021 - The Biden administration is examining ways to ensure that a waiver of COVID-19 vaccine patents to ...

Read more →

Medicines Australia updated position on intellectual property (in light of TRIPS waiver)

6 May 2021 - Medicines Australia continues to express our sympathies to all those affected by the pandemic. The importance ...

Read more →

Australia has backed a global push to fast-track generic COVID-19 jabs

6 May 2021 - The Morrison government has joined an international push to fast-track the production of generic COVID-19 jabs, ...

Read more →

European Patent Office rules in favour of Sanofi and Regeneron concerning Praluent (alirocumab)

29 October 2020 - Ruling invalidates Amgen’s European patent claims directed to PCSK9 antibodies relevant to Praluent (alirocumab). ...

Read more →